In Memoriam
Richard Whittington, M.D.
Member, Penn Clinical Trials Steering Committee, Univeristy of Pennsylvania School of Medicine
Consultant, Univeristy of Pennsylvania School of Medicine, Nuclear Regulatory Commission
Radiation Oncology Chair, University of Pennsylvania School of Medicine, Penn Cancer Center Clinical Trials Group
Member, Radiation Safety Committee, University of Pennsylvania School of Medicine
Member, Radiation Oncology COAP committee, University of Pennsylvania School of Medicine
Department: Radiation Oncology
Contact information
Philadelphia Veterans Medical Center
Department of Radiation Oncology
sub-basement
Philadelphia, PA 19104
Department of Radiation Oncology
sub-basement
Philadelphia, PA 19104
Email:
WHITTINGTON@XRT.UPENN.EDU
WHITTINGTON@XRT.UPENN.EDU
Education:
BA (Biology and History)
Rice University , 1972.
M.D.
Thomas Jefferson University, 1976.
Permanent linkBA (Biology and History)
Rice University , 1972.
M.D.
Thomas Jefferson University, 1976.
Selected Publications
D'Amico AV. Chen MH. Malkowicz SB. Whittington R. Renshaw AA. Tomaszewski JE. Samofalov Y. Wein A. Richie JP: Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml.or less. Journal of Urology 167(5): 2025-30, 2002.D'Amico, A.V., Whittington, R., Malkowicz, S.B., Blank, K., Broderick, G.A., Schultz, D., Tomaszewski, J.E., Wein, A.J. : A prostate specific antigen outcome after permanent interstitial radiation therapy in low risk prostate cancer patients with T2a vs. T1c disease. Int J Rad Oncol Biol Phys 2003.
Jones HA. Metz JM. Devine P. Hahn SM. Whittington R. : Rates of unconventional medical therapy use in patients with prostate cancer: standard history versus directed questions. Urology 59(2): 272-6, 2002.
Lieberfarb ME. Schultz D. Whittington R. Malkowicz B. Tomaszewski JE. Weinstein M. Wein A. Richie JP. D'Amico AV. : Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 53(4): 898-903, 2002.
D'Amico AV. Whittington R. Malkowicz SB. Cote K. Loffredo M. Schultz D. Chen MH. Tomaszewski JE. Renshaw AA. Wein A. Richie JP. : Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 95(2): 281-6, 2002.
Robnett TJ. Whittington R. Malkowicz SB. Brereton HD. Van Arsdalen K. Drach G. Wein AJ.: Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 53(5): 1146-51, 2002.
Cross CK. Shultz D. Malkowicz SB. Huang WC. Whittington R. Tomaszewski JE. Renshaw AA. Richie JP. D'Amico AV: Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. Journal of Clinical Oncology 20(12): 2863-8, 2002.
Whittington, R., Bloch, P., Hutchinson, D., Bjarngard, B. : Verification of prostate treatment setup using computed radiography for portal imaging. J Appl Clin Med Phys 3: 88-96, 2002.
D'Amico AV. Whittington R. Malkowicz SB. Weinstein M. Tomaszewski JE. Schultz D. Rhude M. Rocha S. Wein A. Richie JP: Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. Journal of Urology 166(6): 2185-8, 2001.
Cheung R. Altschuler MD. D'Amico AV. Malkowicz SB. Wein AJ. : ROC optimization may improve risk stratification of prostate cancer patients. Urology. 57(2): 286-90, 2001.